BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 21832990)

  • 1. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study.
    Maeda K; Ikeda Y; Fujita T; Yoshida K; Azuma Y; Haruyama Y; Yamane N; Kumagai Y; Sugiyama Y
    Clin Pharmacol Ther; 2011 Oct; 90(4):575-81. PubMed ID: 21832990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Clinical Cassette Dosing Study for Evaluating the Contribution of Hepatic OATPs and CYP3A to Drug-Drug Interactions.
    Yoshikado T; Maeda K; Furihata S; Terashima H; Nakayama T; Ishigame K; Tsunemoto K; Kusuhara H; Furihata KI; Sugiyama Y
    Pharm Res; 2017 Aug; 34(8):1570-1583. PubMed ID: 28484975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
    Mazzu AL; Lasseter KC; Shamblen EC; Agarwal V; Lettieri J; Sundaresen P
    Clin Pharmacol Ther; 2000 Oct; 68(4):391-400. PubMed ID: 11061579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism.
    Lau YY; Okochi H; Huang Y; Benet LZ
    Drug Metab Dispos; 2006 Jul; 34(7):1175-81. PubMed ID: 16624870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.
    Yoshikado T; Maeda K; Kusuhara H; Furihata KI; Sugiyama Y
    J Pharm Sci; 2017 Sep; 106(9):2739-2750. PubMed ID: 28495568
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
    Jacobson TA
    Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
    Hoch M; Hoever P; Theodor R; Dingemanse J
    Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. effect of OATP1B transporter inhibition on the pharmacokinetics of atorvastatin in healthy volunteers.
    Lau YY; Huang Y; Frassetto L; Benet LZ
    Clin Pharmacol Ther; 2007 Feb; 81(2):194-204. PubMed ID: 17192770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
    Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
    Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.
    Chang JH; Ly J; Plise E; Zhang X; Messick K; Wright M; Cheong J
    Drug Metab Dispos; 2014 Jun; 42(6):1067-73. PubMed ID: 24671957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanisms of pharmacokinetic enhancement between ritonavir and saquinavir; micro/small dosing tests using midazolam (CYP3A4), fexofenadine (p-glycoprotein), and pravastatin (OATP1B1) as probe drugs.
    Ieiri I; Tsunemitsu S; Maeda K; Ando Y; Izumi N; Kimura M; Yamane N; Okuzono T; Morishita M; Kotani N; Kanda E; Deguchi M; Matsuguma K; Matsuki S; Hirota T; Irie S; Kusuhara H; Sugiyama Y
    J Clin Pharmacol; 2013 Jun; 53(6):654-61. PubMed ID: 23381882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin.
    Lilja JJ; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1999 Aug; 66(2):118-27. PubMed ID: 10460065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Efflux transporter-mediated interactions with atorvastatin--interesting findings with multiple substrates: istradefylline, verapamil, and rifampicin.
    Rao N
    J Clin Pharmacol; 2011 May; 51(5):784. PubMed ID: 20671297
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of statins on the pharmacokinetics of midazolam in healthy volunteers.
    Kokudai M; Inui N; Takeuchi K; Sakaeda T; Kagawa Y; Watanabe H
    J Clin Pharmacol; 2009 May; 49(5):568-73. PubMed ID: 19398603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic evaluation of the interaction between hepatitis C virus protease inhibitor boceprevir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and pravastatin.
    Hulskotte EG; Feng HP; Xuan F; Gupta S; van Zutven MG; O'Mara E; Wagner JA; Butterton JR
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2582-8. PubMed ID: 23529734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of Oatp1a/1b-knockout and OATP1B1/3-humanized mice in the study of OATP-mediated pharmacokinetics and tissue distribution: case studies with pravastatin, atorvastatin, simvastatin, and carboxydichlorofluorescein.
    Higgins JW; Bao JQ; Ke AB; Manro JR; Fallon JK; Smith PC; Zamek-Gliszczynski MJ
    Drug Metab Dispos; 2014 Jan; 42(1):182-92. PubMed ID: 24194513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren.
    Vaidyanathan S; Camenisch G; Schuetz H; Reynolds C; Yeh CM; Bizot MN; Dieterich HA; Howard D; Dole WP
    J Clin Pharmacol; 2008 Nov; 48(11):1323-38. PubMed ID: 18784280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Contribution of cytochrome P450 3A4 and 3A5 to the metabolism of atorvastatin.
    Park JE; Kim KB; Bae SK; Moon BS; Liu KH; Shin JG
    Xenobiotica; 2008 Sep; 38(9):1240-51. PubMed ID: 18720283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
    Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
    Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of itraconazole on the pharmacokinetics of atorvastatin.
    Kantola T; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 1998 Jul; 64(1):58-65. PubMed ID: 9695720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.